SOD1 and amyotrophic lateral sclerosis: Tofersen, an oligonucleotide medicine targeting mRNA derived from SOD1 mutation, was clinically approved by the FDA in April, 2023 for the treatment of ALS associated with a mutation in the SOD1 gene [82].